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Abstract
Background: In PET/MRI, linear photon attenuation coefficients for attenuation correction (AC) cannot be directly
derived, and cortical bone is, so far, usually not considered. This results in an underestimation of the average PET
signal in PET/MRI. Recently introduced MR-AC methods predicting bone information from anatomic MRI or proton
density-weighted zero-time imaging may solve this problem in the future. However, there is an ongoing debate if
the current error is acceptable for clinical use and/or research.
Methods: We examined this feature for [18F] fluorodeoxyglucose (FDG) brain PET in 13 patients with clinical signs
of dementia or movement disorders who subsequently underwent PET/CT and PET/MRI on the same day. Multiple
MR-AC approaches including a CT-derived AC were applied.
Results: The resulting PET data was compared to the CT-derived standard regarding the quantification error and its
clinical impact. On a quantitative level, −11.9 to +2 % deviations from the CT-AC standard were found. These deviations,
however, did not translate into a systematic diagnostic error. This, as overall patterns of hypometabolism (which are
decisive for clinical diagnostics), remained largely unchanged.
Conclusions: Despite a quantitative error by the omission of bone in MR-AC, clinical quality of brain [18F]FDG is not
relevantly affected. Thus, brain [18F]FDG PET can already, even now with suboptimal MR-AC, be utilized for clinical routine
purposes, even though the MR-AC warrants improvement.
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Background
No differences in diagnostic quality of the MR compo-
nent in hybrid PET/MR systems as compared to stand-
alone MR systems have been reported [1, 2]. For the
PET component, however, attenuation correction (AC)
systematically differs from that in PET/CT or stand-
alone PET as in PET/MRI the linear photon attenuation
coefficients cannot directly be derived. Hence, the stand-
ard segmentation-based AC currently provided by the
vendors assigns defined attenuation coefficients to differ-
ent tissue classes (usually fat, soft tissue, air) segmented
from a 3D T1-weighted volumetric interpolated breath-
hold examination (VIBE) Dixon sequence. In brain im-
aging, sequential PET/CT vs. PET/MRI cross-evaluation
studies reported an underestimation of the average PET
signal in PET/MRI due to the omission of cortical bone
for several tracers, ranging from 11 to 12 % [3, 4] up to
19 to 25 % [5, 6]. There is an ongoing debate on whether
this error is acceptable for clinical use and/or research.
Moreover, it was recently argued that this problem is
potentially solved with recent AC methods predicting bone
information from anatomic MRI or proton density-
weighted zero-time imaging [7]. Applying the current
standard AC methods, it could be hypothesized that, for
brain [18F] fluorodeoxyglucose (FDG) PET, cortical hypo-
metabolism may be overestimated in PET/MRI, a drawback
which may result in false-positive findings [8]. To test this
hypothesis, we examined 13 patients with clinical signs of
dementia or movement disorders who subsequently under-
went FDG PET/CT and PET/MRI. PET data from PET/
MRI were reconstructed using (1) segmentation-based at-
tenuation maps, (2) continuous μ-maps derived from the
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CT, and (3) continuous μ-maps predicted from high-
resolution anatomical MRI. The respective PET data de-
rived from the outlined reconstruction methods were com-
pared with the gold standard, the PET/CT data, regarding
the quantification error and its clinical impact.
Methods
Thirteen patients with clinical evidence of either demen-
tia or movement disorders underwent brain PET/MRI
and PET/CT of random sequence (n = 7 PET/MRI-first
and n = 6 PET/CT-first). Average time from injection to
PET/CT and PET/MRI did not differ between the PET/
MRI and PET/CT first groups (85 ± 51 vs. 68 ± 38 min,
p = 0.48, two-tailed t test, Table 1). The groups did not
differ in age (59 ± 17 years for PET/CT-first and 69 ±
9 years for PET/MRI-first, p = 0.2, two-tailed t test,
Table 1). After injection of 242 ± 39 MBq FDG, the pa-
tients were placed in a dimly lit and sound-shielded
room to minimize sensory stimulation for at least
30 min before they underwent first imaging. Without a
break, the patients were then transferred to the other
imaging modality to undergo the second brain scan.
PET/MRI
Simultaneous brain PET/MR acquisition was performed
using an integrated PET/MRI system (Siemens mMR
Biograph, Erlangen, Germany, software version VB18P).
Patients were positioned in a dedicated PET/MRI head
coil. Dynamic brain PET data were acquired in 3D list-
mode over 20 min. During PET acquisition, a two-point
MRI Dixon sequence (matrix 128 × 192, 126 slices,
isotropic voxels 2.6 × 2.6 × 2.6 mm3) was acquired. For
attenuation correction, attenuation coefficient maps (air,
soft tissue, fat) were segmented from the fat, and water
images generated by the Dixon sequence and PETDixon
were reconstructed using the built-in OSEM algorithm
with a zoom factor of 2.8, eight iterations, 21 subsets,
and a 3-mm Gaussian filter (256 × 256 matrix, 127 slices,
voxel size 2.8 × 2.8 × 2.03 mm3). Apart from diagnostic
MR sequences, as they were required according to the
clinical question, T1 magnetization-prepared rapid ac-
quisition gradient echo (MPRAGE) data were acquired
in all patients (TE = 2.53 ms, TR = 1900 ms, matrix
512 × 512, 176 slices, voxel size 0.48 × 0.48 × 1 mm3). In
six patients, an additional ultrashort echo time (UTE)
sequence was acquired for μ-map creation with bone in-
formation (TE = 0.07 and 2.46 ms, TR = 11.9 ms, 192 ×
192 × 192 voxels, voxel size 1.6 × 1.6 × 1.6 mm3).
PET/CT
PET/CT was performed on a Biograph 16 (Siemens
Healthcare, Erlangen, Germany). Low-dose CT data for
each patient were obtained (120 kVp, 41 mAs, 512 × 512
matrix, 55 slices, voxel size 0.59 × 0.59 × 3 mm3). Brain
PET data were acquired in 3D mode over 5 min in one
bed position, processed using standard correction
methods, and reconstructed into a 256 × 256 matrix with
55 slices (voxel size 1.3 × 1.3 × 3.0 mm3) using 3D OSEM
with four iterations, eight subsets, and a 5-mm Gaussian
filter, resulting in PETPETCT for each patient. Due to dif-
ferent scanner properties and reconstruction parameters,
PETPETCT was not quantitatively compared to any of the
PET reconstructions from the PET/MRI (PETDixon/CTder-
ived/PseudoCT/BoneDixon). For the same reason, we reduced
the scan time to the lowest possible of 5 min in PET/CT
[9] as opposed to 20 min in PET/MRI. Figure 1 gives an
Table 1 Patient characteristics
Patient Age Gender Activity PET/CT PET/MRI Imaging diagnosis
[years] [MBq] [min p.i.] [min p.i.]
1 70 M 245 38 98 Supranuclear palsy
2 68 F 221 127 35 Unremarkable
3 57 F 215 140 40 Posterior cortical atrophy DD
Alzheimer’s dementia
4 73 F 241 164 35 Unremarkable
5 53 M 248 30 73 Unremarkable
6 74 F 220 119 31 Unremarkable
7 72 F 222 55 85 Unremarkable
8 27 M 217 30 78 Unremarkable
9 79 M 312 134 44 Alzheimer’s dementia
10 60 M 210 131 30 Frontotemporal lobar degeneration
11 65 F 258 31 84 Corticobasal degeneration
12 65 F 211 30 86 Unremarkable
13 67 M 334 69 163 Unremarkable
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overview of the image postprocessing steps and the dif-
ferent PET data obtained for comparative analysis.
PET data postprocessing
(1) The PET data from PET/CT for each subject were
co-registered to the PET data from PET/MRI, using six
degrees of freedom (FLIRT, FSL ToolBox). The resulting
transformation was also used to co-register the CT to
the structural T1 MPRAGE MRI. Successful coregistra-
tion was visually verified and manually corrected if ne-
cessary using PMOD (PMOD 3.4, Zurich, Switzerland).
An MPRAGE-based head mask (brain extraction tool,
FSL ToolBox) was then superimposed on to the co-
registered CT to automatically remove signals from
extra cranial structures such as the CT eye shields and
the CT patient table. CT-Hounsfield units were linearly
transferred to μ values using a bilinear transfer function
as described before [10]. The resulting μ-maps of the
skull and brain were used to replace voxels in the original
Dixon μ-maps (CTderived μ-map). (2) Using a recently
introduced classifier [11], attenuation values for the head
(including bone) were predicted from the anatomical
information from the T1 MPRAGE (PseudoCT μ-map).
(3) As a very simple alternative to the latter, these sophisti-
cated algorithms, a μ-map was generated from the Dixon
and UTE data (if available) imitating the UTE triple-echo
(UTILE) method [4]. The bone information was extracted
from UTE-based μ-maps and was laid over the original
Dixon images using simple algebraic tools (miconv, micalc)
from the ODIN framework (BoneDixon μ-map) [12]. Sub-
sequently, all the resulting manipulated μ-maps were back-
transfered to the console and used for reconstruction of
PETCTderived/PseudoCT/BoneDixon with exactly the same recon-
struction parameters as outlined above (see Fig. 1).
Visual PET image analysis
All PET datasets (PETDixon/CTderived/PseudoCT/BoneDixon
and PETPETCT for each patient) were visually evaluated
in random order by three readers who were experienced
in FDG brain PET data analysis and blinded to the patient
details and diagnosis. For that purpose, the readers evalu-
ated (1) transaxial PET slices of the FDG images, (2) three-
dimensional z-score surface projections as obtained by the
NEUROSTATsoftware [13], and (3) transaxial z-score slices
Fig. 1 FDG brain PET image reconstruction and postprocessing. a PET/CT delivered a low-dose CT (intrasystemly CT-derived μ-map not shown), and the
resulting PETPETCT served as standard of truth for the visual analysis in this study. b PET/MRI was acquired on the same day. Using different μ-maps but the
same reconstruction parameters, four PET datasets were reconstructed in PET/MRI. Dixon-standard Dixon μ-map; CT-derived—Hounsfield units from the
low-dose CT were bilinearly transferred to μ values which replaced values in the original Dixon μ-map; PseudoCT—a pseudo CT was calculated using a T1-
weighted native MRI according to Poynton et al.[11]; BoneDixon-bone voxels μ values from the vendor specific ultrashort echo time (UTE) sequence were
replaced in the original Dixon μ-map. c PETCTderived served as standard for the quantitative analyses across different PET/MRI reconstructions in this study.
For each patient, the percent deviations between and PETDixon/PseudoCT/BoneDixon and PETCTderived were calculated, resulting in relatively small deviations
compared to gold standard PETCTderived if bone was accounted for (top) and larger deviations if bone was ignored (bottom)
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as obtained by the Hermes BRASS software (Hermes Med-
ical Solutions, Stockholm, Sweden). Overall, 12 brain
areas were classified in a binary fashion as either hypo-
metabolic or normal (frontal lobe right/left (r/l), tem-
poral lobe r/l, parietal lobe r/l, occipital lobe r/l,
anterior cingulate gyrus, posterior cingulate gyrus, cere-
bellum r/l). Moreover, the visual evaluation included a
pattern analysis of the hypometabolism, and readers
had to formulate a suspected diagnosis.
Quantitative PET image analysis
Statistical parametric mapping (SPM8; Wellcome
Trust Centre for Neuroimaging, London, UK) was
used to compare the PETCTderived datasets (which were
considered the gold standard) with corresponding
PETDixon/PseudoCT/BoneDixon datasets and to identify
brain areas with divergent PET activity. For this pur-
pose, spatial normalization was determined based on
the co-registered T1-images and smoothing was per-
formed with an 8-mm full-width at half-maximum on
a Gaussian filter. A paired t test was applied for group
comparison. Thresholds were set at p < 0.001, uncor-
rected. Further, to quantify AC-related regional differ-
ences between PETCTderived and the corresponding
PETDixon/PseudoCT/BoneDixon datasets, an atlas-based VOI
analysis was performed by employing the HAMMERS
template in PMOD. The percentage deviation of
PETDixon/PseudoCT/BoneDixon as compared to PETCTderived





Mean images were subsequently averaged across pa-




The volumes of interest (VOI)-based quantificational ana-
lysis revealed that, across all VOIs, there was a −11.9, +2.3,
and −7.4 % deviation of FDG uptake in PETDixon,
PETPseudoCT, and PETBoneDixon compared to PETCTderived.
Detailed results for the single brain areas are provided
in Table 1. The highest uptake differences between
PETCTderived and PETDixon in favor of PETCTderived
were found in the frontal, parietal, and occipital lobes,
and in the cerebellum (~13 to 16 %), while the lowest
differences were found in deeper structures like the
corpus callosum and the ventricles (~2 %). Similarly,
the highest difference between PETBoneDixon and
PETCTderived were detected in the frontal, temporal,
and occipital lobe, and in the cerebellum (~8 to 10 %)
and the lowest were found in the ventricles and the
corpus callosum (~0 to 2 %). In contrast, the uptake dif-
ferences between PETCTderived and PETPseudoCT were
much lower and generally in favor of PETPseudoCT. In the
temporal, frontal, and occipital lobe, and in the cerebel-
lum, differences of up to ~3 to 4 % were found, whereas
the difference in deeper brain structures was negligible
(~0 to 2 % basal ganglia, brainstem, and corpus callosum).
Visual analysis
Using PETPETCT as reference, in nine patients, the hypo-
metabolism was either predominantly unremarkable or
could not be related to any characteristic pathologic pat-
tern so that the suspected diagnosis remained unspecific.
In three patients, an Alzheimer’s dementia (AD) and in
one patient a frontotemporal lobar degeneration (FTLD)
was suspected. In one patient, no coherent suspected
diagnosis could be formulated, and there was a mis-
match compared to PETPETCT according to the majority
decision (Table 2, Fig. 2). This 65-year-old female patient
suffered from a progressive movement disorder with
spasticity in all four limbs, ataxia, and a cerebellar
syndrome—the clinical and imaging-based diagnosis was
corticobasal degeneration. Without knowledge on clinical
symptoms, the blinded readers suspected this PET scan as
either unspecific or considered an AD or a type of FTLD as
the most likely diagnosis. However, no systematic reading
error across the readers and the different PET reconstruc-
tions could be observed in this case. Also, using PETPETCT
as reference, in 85–100 % of patients, the suspected diagno-
sis from PETDixon/CTderived/PseudoCT/BoneDixon was correct for
all readers, whereas none of the reconstructions were infer-
ior to the others.
The number of hypometabolic regions per patient, as
visually assessed, did not differ significantly between PETCT-
derived, PETDixon, PETPseudoCT, and PETBoneDixon in all
readers and ranged from 1 to 2, 1 to 3, and 2 to 3 for
readers 1, 2, and 3 (Table 3). Moreover, for PETCTderived,
PETDixon, PETPseudoCT, and PETBoneDixon, the number of
correctly classified brain regions was determined according
to the standard of truth PETPETCT. When interpreting
Hermes BRASS from PETDixon as compared to PETPseu-
doCT, reader 2 classified significantly more brain regions
correctly (p = 0.012). Apart from that, the number of
correctly classified brain regions did not differ between
PETCTderived, PETDixon, PETPseudoCT, and PETBoneDixon
across patients, and no systematic inferiority of any recon-
struction was observed. Numbers of correctly classified
brain regions ranged from 9 to 11, 10 to 12, and 9 to 11 for
readers 1, 2, and 3 (Table 3).
Statistical parametric mapping (SPM) analysis
The relative FDG uptake was significantly lower in
PETDixon as compared to the reference PETCTderived in
Werner et al. EJNMMI Research  (2016) 6:47 Page 4 of 9
Table 2 Suspected diagnosis in comparison to PETPETCT gold standard
The suspected diagnosis from PETCTderived, PETDixon, PETPseudoCT and PETBoneDixon did either match (green) or mismatch (orange) with the diagnosis from the gold
standard PETPETCT. According to a majority decision, there was a mismatch only in patient 13 for PETPseudoCT and PETBoneDixon. Note: despite the quantificational
difference, the suspected diagnosis for this particular patient did not differ between PETPETCT and PETCTderived according to either of the readers. AD Alzheimer’s
dementia, FTLD frontotemporal lobar degeneration
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a widespread area covering the whole cortex and the
cerebellum (Fig. 3a). The effect was less pronounced
in PETBoneDixon in terms of intensity and level of sig-
nificance but still affected the whole brain. Relative
FDG uptake was significantly higher in PETPseudoCT as
compared to PETCTderived in more restricted areas, in-
cluding the primary and parietotemporal cortices as
well as the cerebellum.
Discussion
In this sequential brain FDG PET/MRI and PET/CT
study in 13 patients, the Dixon μ-map was systematically
complemented by bone information from (1) CT as ob-
tained by PET/CT resulting in PETCTderived, by (2) MR
anatomy information resulting in PETPseudoCT, and (3)
by help of an UTE sequence resulting in PETBoneDixon.
We found that ignoring bone in this patient population
did result in ~12 % uptake underestimation. This is in
line with prior studies stating that due to the omission
of bone, the underestimation of the PET signal ranges
from to 11 to 25 % [3–5]. When using an ultrashort
echo sequence for bone classification or accounting for
cortical bone by use of a recently proposed [11] MR-
based method to predict continuous attenuation values
for the bony skull, the FDG uptake estimation was
improved (~7 % underestimated or ~2 % overestimated).
Also, these results are in line with prior studies [11, 14].
However, to the best of our knowledge, the only FDG
PET study evaluating the clinical impact of different at-
tenuation correction approaches suffered from different
reconstruction parameters and scanner properties [8]. In
our study, the only source of variation between the PET
datasets were the μ-maps themselves; thus, the data was
directly comparable without normalization. This allowed
to study the direct clinical impact of the above-described
AC-related FDG uptake presentation differences on the
clinical FDG brain PET diagnosis. Here, even though the
unaffected cortical PET activity in PETDixon/BoneDixon was
substantially lower, the clinical impact was neglibile;
three experienced readers did not rate systematically
more brain areas as “hypometabolic” after visual inspec-
tion of the PETDixon/CTderived/PseudoCT/BoneDixon slices and
after evaluation of the statistical analyses of the normal-
ized PET data (NEUROSTAT and BRASS). In line with
that, a clinical evaluation of different ACs in comparison
to the gold standard resulted in no differences in the
number of hypometabolic areas as identified by the
readers for each patient. Furthermore, the FDG PET
diagnosis was not more severe in AC approaches that
tend to underestimate the cortical PET signal
Fig. 2 Patient example. Sixty-five-year-old women with clinical and imaging-based diagnosis of corticobasal degeneration. Relative FDG uptake
was severely impaired in the left frontal regions (red arrows). Additionally, there was some degree of relative bilateral uptake deficiency in parietal
areas which was more pronounced in PETDixon but also apparent in PETBoneDixon as compared to PETCTderived (white arrows), resulting in an imaging
diagnosis of Alzheimer’s disease in PETPseudoCT/BoneDixon for reader 1 and in PETDixon/PseudoCT/BoneDixon for reader 2. Note: readers were blinded to the
clinical diagnosis
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(PETBoneDixon, PETDixon) in any of the patients; despite
the above mentioned quantificational difference, the
large proportion of unspecific cases was not misdiag-
nosed as pathologic in PETBoneDixon, and PETDixon as
compared to PETPETCT, PETCTderived, and PETBoneDixon.
Taken together, the quantificational difference by the
omission of bone did not translate into a systematic
diagnostic error in our FDG PET/MRI(CT) study. This
was probably because this global effect may change inten-
sities of apparent cortical hypometabolism but not the
overall pattern of hypometabolism, which is decisive.
Moreover, this global effect did not lead to the typical
decrease-vs.-normal contrast along the gray matter (e.g., the
occipital cortex exhibits normal glucose metabolism and the
adjacent parietal cortex does not in Alzheimer’s dementia).
A limitation of this investigation is the limited number of
subjects examined that does not represent the larger variety
of diseases whose diagnosis is often supported by FDG
brain PET (namely, Alzheimer’s disease, frontotemporal
dementia, dementia with Lewy bodies, Parkinson’s disease,
progressive supranuclear palsy, multiple system atrophy,
corticobasal degeneration, and Huntington’s disease). As a
matter of future research, the evaluation of the impact of
AC-related FDG PET quantificational differences on the
evaluation of patients with atypical parkinsonian syndrome,
like multiple system atrophy or supranuclear palsy, would
be interesting. In these patients, subcortical regions as well
as the cerebellum which is heavily surrounded by bony
structure might also be involved, and the AC-related quan-
tificational error could thus be of clinical relevance.
Moreover, (at least) for research applications, an MR-AC-
related error of ~12 % for FDG brain PET in case of bone
omission needs to be considered and should be further
decreased by the usage of recently introduced MR-based
algorithms to predict continuous μ values. However, the
difference in FDG uptake of 2.3 % between PETPseudoCT
and PETCTderived as observed in this study seems acceptable
for most brain regions even for research applications.
Table 3 Reading results
Reader PETPET/CT PETCTderived PETDixon PETPseudoCT PETBoneDixon
1 Hypometabolic areas (visual) 1.1 ± 1.7 1.3 ± 2.1 1.6 ± 2.0 1.3 ± 1.7 1.7 ± 1.7
Hypometabolic areas (NEUROSTAT) 1.5 ± 2.1 1.8 ± 2.0 2.4 ± 2.1 2.3 ± 2.3 1.9 ± 2.0
Hypometabolic areas (BRASS) 1.1 ± 1.6 1.9 ± 2.6 2.2 ± 2.3 2.1 ± 2.1 2.1 ± 2.1
Correctly classified brain regions compared to PETPET/CT (visual) 10.8 ± 1.7 10.6 ± 1.5 10.5 ± 1.9 9.1 ± 2.3
Correctly classified brain regions compared to PETPET/CT (NEUROSTAT) 10.9 ± 1.7 10.6 ± 1.8 10.7 ± 2 9.6 ± 2.5
Correctly classified brain regions compared to PETPET/CT (BRASS) 10.9 ± 1.7 10.5 ± 1.7 10.7 ± 1.7 9.6 ± 1.7
Correct imaging diagnosis compared to PETPET/CT 11/13 11/13 11/13 7/7
2 Hypometabolic areas (visual) 1.4 ± 2.0 1.4 ± 1.9 1.3 ± 1.7 1.5 ± 2.2 1.7 ± 2.1
Hypometabolic areas (NEUROSTAT) 2.8 ± 3.1 2.1 ± 2.4 2.5 ± 2.8 1.8 ± 2.3 3.0 ± 2.7
Hypometabolic areas (BRASS) 2.2 ± 2.9 1.9 ± 2.4 2.2 ± 2.8 1.1 ± 2.0 1.3 ± 2.1
Correctly classified brain regions compared to PETPET/CT (visual) 11.5 ± 0.7 11.6 ± 0.9 10.8 ± 1.8 11.1 ± 1.1
Correctly classified brain regions compared to PETPET/CT (NEUROSTAT) 11.2 ± 1.1 11.2 ± 1.4 10.4 ± 2.4 10.7 ± 1.7
Correctly classified brain regions compared to PETPET/CT (BRASS) 11.0 ± 1.2 11.4 ± 0.7* 10.4 ± 1.5* 10.1 ± 1.5
Correct imaging diagnosis compared to PETPET/CT 13/13 12/13 12/13 6/7
3 Hypometabolic areas (visual) 1.8 ± 2.5 2.1 ± 1.8 2.6 ± 1.9 2.5 ± 1.9 2.7 ± 1.9
Hypometabolic areas (NEUROSTAT) 2.2 ± 2.5 1.9 ± 1.6 2.5 ± 1.9 2.5 ± 1.8 2.1 ± 1.6
Hypometabolic areas (BRASS) 2.2 ± 2.5 1.9 ± 1.7 2.4 ± 1.7 2.6 ± 1.9 2.1 ± 1.6
Correctly classified brain regions compared to PETPET/CT (visual) 10.8 ± 1.7 10.6 ± 1.5 10.5 ± 1.9 9.1 ± 2.3
Correctly classified brain regions compared to PETPET/CT (NEUROSTAT) 10.7 ± 1.6 10.8 ± 1.3 10.5 ± 1.9 9.1 ± 2.3
Correctly classified brain regions compared to PETPET/CT (BRASS) 10.9 ± 1.7 10.6 ± 2.8 10.7 ± 2.0 9.6 ± 2.5
Correct imaging diagnosis compared to PETPET/CT 11/13 11/13 11/13 7/7
PETPET/CT, PETCTderived, PETDixon, PETPseudoCT, and PETBoneDixon from 13 patients were evaluated by three experienced readers. For each PET, 12 brain areas were
classified as either hypometabolic or normal according to the visual impression and according to the semiquantitiative approaches NEUROSTAT and BRASS. For
PETCTderived, PETDixon, PETPseudoCT, and PETBoneDixon, the number of correctly classified brain regions was determined according to the standard of truth PETPETCT.
Moreover, the readers were asked to formulate an imaging diagnosis on the basis of the PET data without clinical information. The imaging diagnosis was also
compared to the standard of truth PETPETCT. For PETPETCT, PETCTderived, PETDixon, and PETPseudoCT (PETBonedixon), paired (two-sampled) t tests (two-sided; α = 0.05)
were calculated. α was Bonferroni corrected for multiple comparisons. The number of hypometabolic areas across the patients did not differ significantly between
PETCTderived, PETDixon, PETPseudoCT, and PETBoneDixon and the reference: PETPETCT in either of the readers. *Reader 2 classified significantly more brain regions
correctly using BRASS from PETDixon as compared to PETPseudoCT (p = 0.012). Apart from that, the number of correctly classified brain regions did not differ
between PETCTderived, PETDixon, PETPseudoCT, and PETBoneDixon across patients. No systematic inferiority of any reconstruction was observed
Werner et al. EJNMMI Research  (2016) 6:47 Page 7 of 9
Of note, the relative robustness of diagnostic accuracy
against AC-related errors as observed in this present
FDG brain PET study cannot simply be translated to
other PET tracers or to other body regions without fur-
ther investigation. Even though a recent study observed
a similarly limited impact of the Dixon based MR-AC on
clinical diagnosis in amyloid-PET, we would be careful
in assuming that this holds true for neurological PET
studies in general [15]. The contrast between the cortical
signal (on the surface) and the white matter signal (dee-
per location) may compromise the quantification of
cerebral blood flow [16] and may have an impact on the
quantification of amino acid turnover in small tumor
lesions close to the skull [7]. Thus, a standardized
vendor-based implementation of advanced AC algo-
rithms that can provide accurate skull CT surrogates
[11, 17] remains highly desirable for future PET/MRI
systems and their clinical and research applications.
Conclusions
Despite a quantitative error by the omission of bone in
MR-AC, clinical quality of brain [18 F]FDG is not rele-
vantly affected in this patient cohort with suspected demen-
tia and movement disorders. Thus, brain [18 F]FDG PET
can already, even now with suboptimal MR-AC, be utilized
for clinical routine purposes. Advanced AC algorithms that
can provide accurate skull CT surrogates reduced the differ-
ence in FDG uptake to a minimum that is even acceptable
for quantification in research applications.
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Fig. 3 Comparison of different attenuation correction approaches in FDG brain PET/MRI. a Relative FDG uptake comparison by statistical parametric
mapping between PETPseudoCT/BoneDixon/Dixon vs. PETCTderived from the 13 patients investigated (note: PETBoneDixon was available in seven patients only).
Midsagittal and lateral projections: significance level of p < 0.001; T value >3.9 (T > 5.2 for PETBoneDixon due to lower sample size). Relative FDG uptake
was significantly lower in PETDixon/BoneDixon as compared to PETCTderived in a widespread area covering occipital, parietotemporal, and parieto-occipital
cortices as well as the cerebellum. FDG uptake was significantly higher in PETPseudoCT as compared to PETCTderived in more restricted areas, including
the primary and parietotemporal cortices as well as the cerebellum. b Mean images across all patients for the different attenuation correction approaches
(after spatial normalization)
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